Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy
Grail” of AD research and intensively sought; however, there are no well-established …

Increasingly, clinical trials are being planned in patients with mild cognitive impairment (MCI)
to prevent or delay the onset of dementia in Alzheimer disease (AD) by disease-modifying …

The complexity of Alzheimer’s disease (AD) and its long prodromal phase poses challenges
for early diagnosis and yet allows for the possibility of the development of disease modifying …

Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE)
ε4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament …

Blood-based biomarkers represent a less invasive and potentially cheaper approach for
aiding Alzheimer’s disease (AD) detection compared with cerebrospinal fluid and some …

Introduction Machine learning (ML) may harbor the potential to capture the metabolic
complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in …

Introduction A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of
peripheral small molecule biomarkers. Given that brain pathology precedes clinical …

Introduction Plasma proteins have been widely studied as candidate biomarkers to predict
brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical …

Artificial intelligence (AI) approaches pose a great opportunity for individualized, pre-symptomatic
disease diagnosis which plays a key role in the context of personalized, predictive, …

Background Measures of neocortical amyloid burden (NAB) identify individuals who are at
substantially greater risk of developing Alzheimer's disease (AD). Blood-based biomarkers …